Observational studyAmerican journal of clinical dermatology2026
Long-Term Real-World Evaluation of Abrocitinib in Moderate-to-Severe Atopic Dermatitis Across a Diverse Patient Population in a Multi-site Hospital System.
Observational study in American journal of clinical dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAlthough clinical trials have demonstrated the efficacy and safety of abrocitinib in atopic dermatitis, there remains a lack of comprehensive long-term real-world studies across diverse patient populations.
objectiveWe aimed to characterize long-term treatment responses and adverse events of abrocitinib in adults with moderate-to-severe atopic dermatitis in real-world daily practice.
methodsWe conducted a retrospective observational study of adults with moderate-to-severe atopic dermatitis who were treated with abrocitinib between 1 January, 2022 and 1 January, 2025 at a multi-site hospital system. Final follow-up was defined as each patient's last documented clinic visit before 1 January, 2025. Primary outcomes were changes in clinical severity scores from baseline to the final follow-up. Secondary outcomes included 1-year clinical response rates, laboratory trends, adverse events, and treatment discontinuations.
resultsWe identified 50 adults with moderate-to-severe atopic dermatitis (mean age 40 ± 14 years; 56% female) who had been treated with abrocitinib. Most (96%) had not responded to prior systemic therapies, including dupilumab (80%) and prednisone (36%). Clinical response improved over time: at 12-24 weeks (n = 33), 43.5% achieved an improvement of 75% or more in the Eczema Area and Severity Index (EASI-75) and 42.9% achieved an Investigator's Global Assessment (IGA) 0/1; by 36-48 weeks (n = 18), these rates rose to 53.9% and 45.5%, respectively. After 1 year (n = 29), 52.6% maintained EASI-75 and 56.5% achieved IGA 0/1. Final follow-up showed significant reductions from baseline in IGA (- 48.5%), body surface area (- 60.3%), and EASI (- 58.6%) [all p < 0.0001]. Adverse events were mild, the most common were acne (8%) and nausea (6%).
conclusionsIn our real-world study, adults with moderate-to-severe atopic dermatitis treated with abrocitinib had a progressive sustained clinical improvement across various races, ages, doses, disease onsets, atopic comorbidities, and body mass index ranges.
Indexed as
Identifiers
41591740What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.